Gates Foundation Funded French Research Group Commences Ivermectin Clinical Trial Targeting COVID-19

Apr 15, 2020 | Coronavirus, COVID-19, France, Ivermectin, Leading Sites, Medincell, News, Site Success, Site Watch

Gates Foundation Funded French Research Group Commences Ivermectin Clinical Trial Targeting COVID-19

Australian researchers recently created a lot of interest in Ivermectin as they found it could zap COVID-19 in vitro. At least some French doctors have come out in support of more testing of the anti-parasitic drug, which they believe could be more effective against COVID-19 than chloroquine. Medincell’s work is funded by a $6.4 M grant from Unitaid. They have now launched a clinical trial to investigate if it can work on COVID-19 in humans. The momentum gains to generate meaningful clinical data.

Background

TrialSite News received great interest after it published a story about Australian researchers’ findings in regards to ivermectin. The topic generated thousands of reads and hundreds of messages to the Salt Lake City, Utah-based clinical trials-focused media and social network venture. Monash University’s Biomedicine Discovery Institute and Peter Doherty Institute of Infection and Immunity at Royal Melbourne Hospital published the results of a study revealing that the drug, an approved anti-parasitic available worldwide, may actually treat against SARS-CoV-2—at least when applied to an infected cell culture in a laboratory. The results were very promising as they found after 48 hours the drug was found to have reduced the viral load of the novel coronavirus from 5,000 units to just one unit—representing a reduction of 99.98%.

One of the preclinical researchers, Dr. Kylie Wagstaff from Monash University told a French paper called Le Parisien that “Researchers had the idea to test this [drug] that we use against scabies, to see if it could have an effect on the coronavirus.”

Enter Medincell

Now this got the attention of clinical investigators in Medincell, a French pharmaceutical research venture adjacent to Montpellier. As it turns out, this group had received a $6.4 M grant from Unitaid to test ivermectin as a treatment against malaria. Given the world’s state—a major pandemic and the overlap of interest and drug—the French group got to work. According to David Heuzé, communications director at Medincell, “We now need clinical trials to check the potential of the cure on human beings.”

French Perspective: ‘Why not try it’?

Pragmatically assessing the current crisis, Professor Jean-Paul Stahl, head of the infectious diseases unit at Grenoble CHU hospital, reported to ConnexionFrance, “Ivermectin is an old medicine. Like chloroquine, it is an anti-parasitical drug, but they are not all the same chemical compound.” Professor Stahl continued, “Taking the urgency into account, it would be impossible to create a new drug against COVID-19. This would take at least three years minimum. This drug [ivermectin] already exists and is available. So why not [try it]?”

An investigator and professor from the French Académie Nationale de Médecine and infectious disease specialist added in the ConnexionFrance, “Beyond this initial work, we must check and continue to research to see if it works on humans.”

Medincell Position to Date

Medincell reported recently on their website that they have published data revealing that long-acting formulations of Ivermectin can be designed with varying doses and durations with its BEPO® technology and is already landing a program aiming at developing a 3-month injectable product to fight malaria.

Now the French venture has launched a research initiative on a long-acting injectable formulation of Ivermectin and the group believes that it could have a role to play in COVID-19 management. They note that future clinical studies must confirm the action of Ivermectin on the COVID-19 virus, and the potential effectiveness of a long-acting injectable on its prevention and therefore breaking the chain of transmission. Should the results be positive from their clinical study, a BEPO® technology-based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.

About Medincell

Medincell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, Medincell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

Call to Action: Interested in tracking the Medincell Ivermectin clinical trial targeting COVID-19? Sign up for the Daily Newsletter and joint the TrialSite Network. Interested in connecting to partner? David Heuzé heads their communications and corporate development. 

Source: Medincell

14 Comments

  1. Rodolfo Elias Rodriguez

    I would like to be a patient for the study.

    I tested positive for covid 19. And I am currently taking Ivermectin.

    • Alexei Gretchikha

      How long have you been taking it? Have you noticed any effect?

    • Payampazhouhesh

      Hello, i hope you to be fine and get better. I would be happy if you tell me about your ivermectin dosage that you use now and your condition after using it. I realy very anxious about my old dady. Thank you

    • Pablo var bri

      Dose it work?

  2. Dr. Jerry Sellon I

    Interesting to see if it clears the few animals that have tested positive.

    • TrialSite

      Dear Dr. Sellon,
      Thanks for visiting TrialSite News. We agree it is interesting. We received enormous interest in this drug. We are undertaking more research and tracking any progress in the small study in France.
      Regards,
      Publisher

    • Patrick

      I started to have symptoms before knowing about Covid19. I though it may be a parasite infection so I took Piprazine and then Fenbenzadole. Later that day all my issues cleared up.

  3. Carl

    Bill Gates wants to string you along for three years doing “clinical trials” on ivermectin while he works on getting mandated vaccines passed into law (HIS vaccines). Don’t forget Bill Gates doesn’t vaccinate his own family.

    Meanwhile people today are finding out that hydroxychloroquine actually DOES work.

    • Frederick

      Doctors are already using invermectin in all Broward Health hospitals in South Florida. All patients treated showing successful recovery. Why noone reporting more on this, idk??

      • TrialSite

        Dear Frederick,
        Yes we reported on the Broward County doctor and the fact that his protocol was accepted by Broward County Health. Moreover on Sunday we updated the TrialSite Network about two clinical trials using Ivermectin at Tanta University in Egypt. Not sure what is going on with the lack of reporting. What are some of your thoughts on that subject?
        Best Regards,
        Publisher

        • Frederick

          Don’t want to speculate or sound like a conspiracy theorist. But some say bad news sales for mainstream media better than good news. Also, how do I subscribe to follow trials?

          • TrialSite

            Hello- Sorry for the late reply- currently we have our newsletter that goes out every night with the most recent news. We are working on some other things that will allow you to fine tune that a bit in the future. If you’d like to sign up you can do so on our homepage on the right hand side, or I can do it for you with your permission.

          • TrialSite

            Dear Frederick,
            Firstly thanks for visiting TrialSIte News. Your visits, support and comments contribute to the dynamic nature of this rapidly growing media platform representing a network of tends of thousands interested in good, sound clinical research that helps people’s health.
            One only need to watch a local news channel across America to know what sells-bad news. However, there is good news happening all around us all the time; people doing amazing things–small and big things that make a difference. We try to cover that here. What has amazed us during this whole COVID-19 event is how many incredibly smart, talented and/or dedicated health professionals have got involved some way, some how to help others. Within what we call the TrialSite Network we have supported dozens of doctors wanting to get into research to take on the virus. And hundred of people that think they had the condition sought out to participate in research. So no matter how bad the conditions appear, the proverbial glass is half full as we will all collectively pull through this and hopefully, learn from what didn’t work. Sign up for the newsletter and you become part of the TrialSite Network–that is an exciting portal that enables more tailored input to track research, share information and connect with others.
            Thanks again for visiting Frederick,
            Publisher

  4. Yusuf Adeojo

    Maybe you need to lobby the new houses abit.

    I mean they jumped on the new drug “ remdesivir” and the result was inconclusive.

    Also you have to be more aggressive with your Social Media publication. If the News houses don’t drive it, social media will, which will force them to report on it